Key result
The vented electric Heartmate LVAD successfully rehabilitated 4 men with end-stage cardiomyopathy to NYHA Class I status, enabling safe outpatient management.
Why the study?
Does the vented electric Heartmate LVAD allow safe outpatient management in patients with end-stage cardiomyopathy?
Case Report (n=4)
Does the vented electric Heartmate LVAD allow safe outpatient management in patients with end-stage cardiomyopathy?
The vented electric Heartmate LVAD safely allows selected patients with end-stage cardiomyopathy to undergo outpatient treatment while awaiting heart transplantation.
Supports feasibility of outpatient LVAD management in selected cases; leaves open need for prospective validation before broader adoption.
The vented electric Heartmate LVAD (VE-LVAD) (Thermo Cardiosystems, Inc., Woburn, MA) is a reliable, fully portable system that allows selected patients with end-stage cardiomyopathy to undergo outpatient treatment while waiting for heart transplantation. This implantable, pusher-plate LVAD is actuated by an electric motor located within the pump housing. The patient wears external batteries and a system controller, which power and control the LVAD motor through a percutaneous lead. Since May 1991, four men have been supported with the VE-LVAD. They ranged in age from 33 to 50 years (mean, 44.3 years); two had idiopathic cardiomyopathy, and two had ischemic cardiomyopathy. Of the four patients, three underwent support of 196, 219, and 504 days; support in the fourth patient is ongoing at more than 90 days. All four patients were fully rehabilitated to New York Heart Association Class I status. Because they were well and fully mobile, the protocol was amended to allow these patients to leave the hospital in a four phase program that begins with 16 hr day passes and leads to hospital discharge. When patients leave the hospital, they are accompanied by trained family members or friends. The patients who have participated in the program have performed routine activities, attended social events, and spent the night at home. The VE-LVAD system seems safe and appropriate for the outpatient setting in selected patients. Patients have been able to manage the system without assistance from medical or engineering personnel. This initial positive experience with outpatient LVAD treatment demonstrates the potential for providing long-term cardiac support with this type of implantable technology.
No takes yet. Share an insight, caveat, or question.
Myers et al. (1994) conducted a case report in End-stage cardiomyopathy (n=4). Vented electric Heartmate LVAD (VE-LVAD) was evaluated on Rehabilitation to New York Heart Association Class I status. The vented electric Heartmate LVAD successfully rehabilitated 4 men with end-stage cardiomyopathy to NYHA Class I status, enabling safe outpatient management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: